Page 1324 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 92

REFERENCES

1. Appelbaum FR, Baer MR, Carabasi MH, et al. NCCN Practice 15. De Botton S, Dombret H, Sanz M, et al. Incidence, clinical
Guidelines for Acute Myelogenous Leukemia. Oncology features, and outcome of all trans-retinoic acid syndrome in 413
(Williston Park). 2000;14:53. cases of newly diagnosed acute promyelocytic leukemia. The
2. Bennett JM, Brunning RD, Vardiman JW. Myelodysplastic European APL Group. Blood. 1998;92:2712.
syndromes: from French-American-British to World Health 16. DeSancho MT, Berlus N, Christos PJ, et al. Risk factors for clini-
Organization: a commentary. Blood. 2002;99:3074. cal manifestations in carriers of Factor V Leiden and prothrom-
3. Betz BL, Hess JL. Acute myeloid leukemia diagnosis in the bin gene mutations. Blood Coagul Fibrinolysis. 2010;21:11.
21st century. Arch Pathol Lab Med. 2010;134:1427. 17. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans reti-
4. Blum W, Garzon R, Klisovic RB, et al. Clinical response and noic acid plus arsenic trioxide as an alternative to chemotherapy
miR-29b predictive significance in older AML patients treated in untreated acute promyelocytic leukemia. Blood. 2006;107:3469.
with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 18. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic
2010;107:7473. leukemia: concepts and strategies. Cancer. 2010;116:1165.
5. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and 19. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transreti-
hyperviscosity syndrome. Semin Thromb Hemost. 2007;33:350. noic acid in newly diagnosed acute promyelocytic leukemia.
6. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal Results of a multicenter randomized trial. European APL 91
karyotype in acute myeloid leukemia: a better indicator of poor Group. Blood. 1993;82:3241.
prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791. 20. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice
7. Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on guideline for the use of antimicrobial agents in neutropenic
early death rate in adult acute myeloid leukemia presenting with patients with cancer: 2010 update by the infectious diseases
hyperleukocytosis. Transfusion. 2007;47:1843. society of america. Clin Infect Dis. 2011;52:e56.
8. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic 21. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance
abnormalities are predictive of induction success, cumulative of activating FLT3 mutations in younger adults (16 to 60 years)
incidence of relapse, and overall survival in adult patients with with acute myeloid leukemia and normal cytogenetics: a study
de novo acute myeloid leukemia: results from Cancer and of the AML Study Group Ulm. Blood. 2002;100:4372.
Leukemia Group B (CALGB 8461). Blood. 2002;100:4325. 22. Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces
9. Byrd JC, Weiss RB, Arthur DC, et al. Extramedullary leukemia early mortality in patients with acute myeloid leukemia with
adversely affects hematologic complete remission rate and high white cell counts but does not improve long-term survival.
overall survival in patients with t(8;21)(q22;q22): results from Leuk Lymphoma. 2001;42:67.
Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15:466. 23. Green D. Management of bleeding complications of hemato-
10. Carlson KS, DeSancho MT. Hematological issues in critically ill logic malignancies. Semin Thromb Hemost. 2007;33:427.
patients with cancer. Crit Care Clin. 2010;26:107. 24. Hardee ME, Arcasoy MO, Blackwell KL, et al. Erythropoietin
11. Coiffier B, Altman A, Pui CH, et al. Guidelines for the manage- biology in cancer. Clin Cancer Res. 2006;12:332.
ment of pediatric and adult tumor lysis syndrome: an evidence- 25. Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone
based review. J Clin Oncol. 2008;26:2767. and etoposide in refractory acute myelogenous leukemia—an
12. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. active and well-tolerated regimen. J Clin Oncol. 1988;6:213.
fluconazole or itraconazole prophylaxis in patients with neutro- 26. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a mul-
penia. N Engl J Med. 2007;356:348. ticenter study for treatment of acute lymphoblastic leukemia in
13. Cullen M, Baijal S. Prevention of febrile neutropenia: use of adults. Blood. 1988;71:123.
prophylactic antibiotics. Br J Cancer. 2009;101(suppl 1):S11. 27. Howard SC, Pui CH. Pitfalls in predicting tumor lysis syn-
14. Darmon M, Guichard I, Vincent F, et al. Prognostic signifi- drome. Leuk Lymphoma. 2006;47:782.
cance of acute renal injury in acute tumor lysis syndrome. Leuk 28. Hunault-Berger M, Chevallier P, Delain M, et al. Changes
Lymphoma. 2010;51:221. in antithrombin and fibrinogen levels during induction

Section07-O-ref.indd 1 1/21/2015 11:26:50 AM